

---

---

**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(D)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): June 23, 2020**

---

**INTERNATIONAL STEM CELL CORPORATION**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-51891**  
(Commission  
File Number)

**20-4494098**  
(IRS Employer  
Identification Number)

**5950 Priestly Drive, Carlsbad, CA 92008**  
(Address of principal executive offices, including zip code)

**(760) 940-6383**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading<br>Symbol(s) | Name of each exchange<br>on which registered |
|---------------------|----------------------|--|
| None                | N/A                  | N/A  |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

**ITEM 5.07 Submission of Matters to a Vote of Security Holders**

International Stem Cell Corporation (the “Company”) held its Annual Meeting of Stockholders on June 23, 2020. The stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement dated June 1, 2020.

**Proposal 1:** Election of four directors to hold office until the 2021 Annual Meeting:

A. Directors elected by holders of Series D Preferred Stock:

|                  | <b>FOR</b> | <b>WITHHELD</b> |
|------------------|------------|-----------------|
| Andrey Semechkin | 2,457,143  | 0               |
| Russell Kern     | 2,457,143  | 0               |

B. Directors elected by holders of all shares of stock (including shares of preferred stock voting on an as-converted basis):

|                  | <b>FOR</b> | <b>WITHHELD</b> |
|------------------|------------|-----------------|
| Donald A. Wright | 7,306,434  | 39,555          |
| Paul V. Maier    | 7,305,768  | 40,221          |

Broker Non-Votes: none

All of the foregoing candidates were elected.

**Proposal 2:** To approve an amendment to the 2010 Equity Participation Plan (including shares of preferred stock voting on an as-converted basis):

| <b>FOR</b> | <b>AGAINST</b> | <b>ABSTAIN</b> |
|------------|----------------|----------------|
| 7,282,153  | 51,838         | 11,988         |

Broker Non-Votes: none

The foregoing proposal was approved.

---

### Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### **International Stem Cell Corporation**

By: /s/ Sophia Gamette

Sophia Gamette

Vice President, Legal Affairs and Operations

Dated: June 29, 2020